Skyhawk Therapeutics

Private

#Neurology #Oncology #Autoimmune Diseases #Fibrotic Diseases #Neurodegeneration

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA splicing modulators using its proprietary SkySTAR platform, with programs in neurology, oncology, autoimmune, and fibrotic diseases.

Company Info

Sector:Small Molecule Pharma

Headquarters:Waltham, Massachusetts, United States

Founded:2016

Website:www.skyhawktx.com/

Funding Round:Series C and partnership milestones

Total Funding:>$2B in pharma partnership economics (incl. $2B+ Merck KGaA deal)

Funding & Investor Relations

Notable Investors

Bain Capital Life Sciences
Verition Fund Management
Healthcare-focused institutional investors

Upcoming Milestones & Key Dates

2026-Q3

Clinical readout

SKY-0515 interim FALCON-HD data

2026-Q4

Regulatory

Additional IND filings

Clinical Development Pipeline

SKY-0515

Target: HTT RNA splicing

Huntington's disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SKY-1215

Target: RNA splicing

Oncology (multiple programs)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BMS-partnered program

Target: RNA splicing

Multiple (undisclosed)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Bill Haney

Chief Executive Officer

Aaron Deves

Chief Commercial Officer

Kyle Dow

Vice President, Corporate Development

Careers & Job Openings

See all open roles

Careers

Waltham, Massachusetts, United States

Apply Now →